Mylan Spooks Investors With Surprise Plans For Higher 2019 Spending

Investors sold shares in Mylan after its management unexpectedly announced that it would increase sales and marketing expenses significantly in 2019 to boost growth of complex products that are now a much bigger portion of the generic and specialty drugmaker's revenue.